NO315904B1 - Fremgangsmåte for fremstilling av anti-human antigenreseptor, humant antistoff, samt av farmasöytisk preparat - Google Patents

Fremgangsmåte for fremstilling av anti-human antigenreseptor, humant antistoff, samt av farmasöytisk preparat Download PDF

Info

Publication number
NO315904B1
NO315904B1 NO19994983A NO994983A NO315904B1 NO 315904 B1 NO315904 B1 NO 315904B1 NO 19994983 A NO19994983 A NO 19994983A NO 994983 A NO994983 A NO 994983A NO 315904 B1 NO315904 B1 NO 315904B1
Authority
NO
Norway
Prior art keywords
human
antigen
antibody
chains
chain
Prior art date
Application number
NO19994983A
Other languages
English (en)
Norwegian (no)
Other versions
NO994983L (no
NO994983D0 (no
Inventor
Peter Kufer
Tobias Raum
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of NO994983D0 publication Critical patent/NO994983D0/no
Publication of NO994983L publication Critical patent/NO994983L/no
Publication of NO315904B1 publication Critical patent/NO315904B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19994983A 1997-04-14 1999-10-13 Fremgangsmåte for fremstilling av anti-human antigenreseptor, humant antistoff, samt av farmasöytisk preparat NO315904B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97106109 1997-04-14
PCT/EP1998/002180 WO1998046645A2 (en) 1997-04-14 1998-04-14 Method for the production of antihuman antigen receptors and uses thereof

Publications (3)

Publication Number Publication Date
NO994983D0 NO994983D0 (no) 1999-10-13
NO994983L NO994983L (no) 1999-12-07
NO315904B1 true NO315904B1 (no) 2003-11-10

Family

ID=8226694

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994983A NO315904B1 (no) 1997-04-14 1999-10-13 Fremgangsmåte for fremstilling av anti-human antigenreseptor, humant antistoff, samt av farmasöytisk preparat

Country Status (24)

Country Link
US (1) US7227002B1 (cs)
EP (1) EP0970126B1 (cs)
JP (1) JP3876002B2 (cs)
KR (2) KR100663319B1 (cs)
CN (1) CN100387621C (cs)
AT (1) ATE200679T1 (cs)
AU (1) AU742045B2 (cs)
BR (1) BRPI9809391B8 (cs)
CA (1) CA2286879C (cs)
CU (1) CU23268A3 (cs)
CZ (1) CZ294425B6 (cs)
DE (1) DE69800716T2 (cs)
DK (1) DK0970126T3 (cs)
ES (1) ES2172149T3 (cs)
GR (1) GR3036229T3 (cs)
HU (1) HU221818B1 (cs)
IL (2) IL132062A0 (cs)
NO (1) NO315904B1 (cs)
PL (1) PL193780B1 (cs)
PT (1) PT970126E (cs)
RU (1) RU2224766C2 (cs)
SI (1) SI0970126T1 (cs)
TR (1) TR199902553T2 (cs)
WO (1) WO1998046645A2 (cs)

Families Citing this family (473)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
WO1999047538A1 (en) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US7189405B1 (en) * 1999-10-29 2007-03-13 Rice Peter A Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
WO2002043660A2 (en) 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
AU2002250032B2 (en) 2001-02-09 2008-06-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
MXPA03009924A (es) * 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
WO2003104428A2 (en) 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
US7371383B2 (en) 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP2371389A3 (en) 2002-08-14 2012-04-18 MacroGenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
SI1551876T1 (sl) 2002-10-16 2011-07-29 Purdue Pharma Lp Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
AU2003299778A1 (en) 2002-12-20 2004-07-22 Protein Design Labs, Inc. Antibodies against gpr64 and uses thereof
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7259002B2 (en) 2003-01-21 2007-08-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
WO2004073624A2 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
EP2100619B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders
GEP20094629B (en) 2003-03-19 2009-03-10 Biogen Idec Inc Nogo receptor binding protein
ES2391087T3 (es) 2003-04-11 2012-11-21 Medimmune, Llc Anticuerpos de IL-9 recombinantes y usos de los mismos
US20070243201A1 (en) * 2003-06-02 2007-10-18 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag Method for Selecting Epitopes for Immunotherapy
JP2008500005A (ja) 2003-07-15 2008-01-10 バロス リサーチ インスティテュート 癌及び感染症の免疫療法のための組成物及び方法
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
JP2007511738A (ja) 2003-08-08 2007-05-10 ジーンニュース インコーポレーテッド 変形性関節症のバイオマーカー及びその使用
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
WO2006002437A2 (en) 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
EP2329714A1 (en) 2004-08-03 2011-06-08 Biogen Idec MA Inc. Influence of TAJ in the neuronal functions
NZ553162A (en) 2004-08-16 2010-03-26 Quark Biotech Inc Double stranded siRNA compounds that inhibit RRTP801
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP3073267A1 (en) 2004-09-21 2016-09-28 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2006086242A2 (en) 2005-02-07 2006-08-17 Genenews, Inc. Mild osteoarthritis biomarkers and uses thereof
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
WO2006096565A2 (en) 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
JP2008545712A (ja) 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
SG10201508322SA (en) 2005-07-08 2015-11-27 Biogen Ma Inc Sp35 antibodies and uses thereof
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
WO2007048074A1 (en) 2005-10-21 2007-04-26 Genenews Inc. Method and apparatus for correlating levels of biomarker products with disease
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
EP2510934A1 (en) 2005-11-04 2012-10-17 Biogen Idec MA Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
CN101500592A (zh) 2005-11-07 2009-08-05 斯克利普斯研究院 控制组织因子信号转导特异性的组合物和方法
GB2447187C (en) 2005-12-02 2015-02-04 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
NZ598421A (en) 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
WO2007068488A1 (en) * 2005-12-15 2007-06-21 Micromet Ag Domain-grafted antibodies
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
CA2640423C (en) 2006-01-27 2016-03-15 Biogen Idec Ma Inc. Nogo receptor antagonists
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080070792A1 (en) 2006-06-14 2008-03-20 Roland Stoughton Use of highly parallel snp genotyping for fetal diagnosis
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
JP2009544761A (ja) 2006-06-14 2009-12-17 マクロジェニクス，インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
DK2029173T3 (en) 2006-06-26 2016-11-07 Macrogenics Inc FC-RIIB-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2044122B1 (en) 2006-07-18 2018-03-28 Sanofi Antagonist antibody against epha2 for the treatment of cancer
KR101374983B1 (ko) 2006-08-28 2014-03-17 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체를 포함하는 제약 조성물
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
BRPI0719409A2 (pt) 2006-12-18 2014-02-11 Genentch Inc "regiões variáveis da cadeia pesada ("vh"), sequências da cadeia vh, ácido nucléico, vetor, célula, anticorpos, uso do anticorpo, método para produzir um anticorpo, anticorpo anti-notch3 e forma humanizada do anticorpo"
DK2436696T3 (en) 2007-01-05 2017-09-04 Univ Zuerich Anti-beta-amyloid antibody and uses thereof
EP2740744B1 (en) 2007-01-09 2018-03-28 Biogen MA Inc. Sp35 antibodies and uses thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
JP5456658B2 (ja) 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
PT2068927E (pt) 2007-05-14 2016-02-10 Medimmune Llc Métodos para reduzir os níveis de eosinófilos
PL2158221T3 (pl) 2007-06-21 2019-02-28 Macrogenics, Inc. Kowalencyjne diaciała i ich zastosowania
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
UA117446C2 (uk) 2007-08-29 2018-08-10 Санофі-Авентіс Гуманізоване антитіло до cxcr5
PL2193142T3 (pl) 2007-08-30 2015-06-30 Curedm Group Holdings Llc Kompozycje i sposoby z zastosowaniem peptydów prowysepkowych i ich analogów
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
MX2010004814A (es) 2007-11-05 2010-08-10 Medimmune Llc Metodos para tratar esclerodermia.
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
AR069981A1 (es) 2007-12-26 2010-03-03 Biotest Ag Los "anticuerpo modificado geneticamente que reconocen cd138".
DK2242772T3 (en) 2007-12-26 2015-01-05 Biotest Ag Immunoconjugates that targets CD138, and uses thereof
AR069978A1 (es) 2007-12-26 2010-03-03 Dana Farber Cancer Inst Inc Metodos y agentes para mejorar el reconocimiento de celulas de tumor que expresan cd 138
AR069979A1 (es) 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
CN102083460A (zh) 2008-01-18 2011-06-01 米迪缪尼有限公司 用于位点特异性偶联的半胱氨酸工程化抗体
DK2250279T3 (en) 2008-02-08 2016-08-01 Medimmune Llc ANTI-IFNAR1 antibodies with reduced Fc ligand affinity-
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
CA2722043A1 (en) 2008-04-25 2009-10-29 Toray Industries, Inc. Nucleic acid comprising chimeric gene derived from hepatitis c virus
WO2009135181A2 (en) 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
EP2982695B1 (en) 2008-07-09 2019-04-03 Biogen MA Inc. Compositions comprising antibodies to lingo or fragments thereof
JP2012500634A (ja) * 2008-08-29 2012-01-12 シムフォゲン・アクティーゼルスカブ 鳥類から得られた抗体のクローニング方法
KR101442323B1 (ko) 2008-09-07 2014-09-25 글라이코넥스 인코포레이티드 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
ES2620294T3 (es) 2008-09-20 2017-06-28 The Board Of Trustees Of The Leland Stanford Junior University Diagnóstico no invasivo de la aneuploidia fetal por secuenciación
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
RU2593720C2 (ru) 2008-12-19 2016-08-10 Макродженикс, Инк. Ковалентные диантитела и их применение
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
EP2389195B1 (en) 2009-01-20 2015-05-20 Homayoun H. Zadeh Antibody mediated osseous regeneration
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EP2405920A1 (en) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
RU2542394C2 (ru) 2009-03-24 2015-02-20 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Гуманизированные антитела против light и их применение
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
US8921281B2 (en) 2009-05-20 2014-12-30 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
UA104626C2 (ru) 2009-06-17 2014-02-25 Эббви Биотерапеутикс Инк. Анти-vegf антитело и его применение
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
EP2464664B1 (en) 2009-08-13 2015-09-23 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
LT2486141T (lt) 2009-10-07 2018-05-25 Macrogenics, Inc. Fc regioną turintys polipeptidai, pasižymintys pagerinta efektorine funkcija dėl fukozilinimo laipsnio pasikeitimų, ir jų naudojimo būdai
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
CA2777825A1 (en) 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
EP2496243A2 (en) 2009-11-04 2012-09-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
ES2594893T3 (es) 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anticuerpos anti HER2 y sus usos
MX350983B (es) 2010-02-08 2017-09-27 Regeneron Pharma Raton de cadena ligera comun.
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
CA3188287C (en) 2010-03-26 2025-07-08 Memorial Sloan Kettering Cancer Center Antibodies to muc16 and methods of use thereof
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
EP2561076A1 (en) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
EP2580239A1 (en) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
EP2585097B1 (en) 2010-06-25 2018-09-26 Aston University Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
JP6121906B2 (ja) 2010-10-22 2017-04-26 シアトル ジェネティクス，インコーポレーテッド アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴｍＴＯＲ経路インヒビターの間の相乗効果
WO2012065937A1 (en) 2010-11-15 2012-05-24 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2012083370A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
CN103620405B (zh) * 2010-12-31 2016-05-25 生物蛋白有限公司 全面单克隆抗体产生
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
ES2605784T3 (es) 2011-05-21 2017-03-16 Macrogenics, Inc. Dominios de enlazamiento a suero desinmunizados y su uso para extender la vida media en suero
EP2717911A1 (en) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
AU2012294624B2 (en) 2011-08-05 2015-08-13 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
CA2845536A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
AU2012306341B2 (en) 2011-09-09 2017-08-31 Cambridge Enterprise Limited Anti-Siglec-15 antibodies and uses thereof
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
EP2776022A1 (en) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
SG11201402887SA (en) 2011-12-08 2014-07-30 Biotest Ag Uses of immunoconjugates targeting cd138
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
CN104471064B (zh) 2012-01-20 2018-11-02 中华人民共和国香港特别行政区政府 副粘病毒及其用途
CN104254778A (zh) 2012-02-10 2014-12-31 西雅图遗传学公司 Cd30+癌症的检测和治疗
DK2814842T3 (en) 2012-02-15 2018-12-10 Novo Nordisk As ANTIBODIES BINDING PEPTIDOGLYCAN RECOGNITION PROTEIN 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
CN104168916B (zh) 2012-03-02 2017-07-04 中央研究院 抗上皮细胞黏着分子(EpCAM)抗体及其使用方法
SG11201405171WA (en) 2012-03-16 2014-10-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
CN107840890A (zh) 2012-03-16 2018-03-27 瑞泽恩制药公司 组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US9663581B2 (en) 2012-04-25 2017-05-30 Momenta Pharmaceuticals, Inc. Modified glycoproteins
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
MX362497B (es) 2012-05-15 2019-01-21 Eisai Inc Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EP2869818A1 (en) 2012-07-06 2015-05-13 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
EP3730512A1 (en) 2012-07-13 2020-10-28 The Trustees of the University of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
WO2014018747A2 (en) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
EP2904106A4 (en) 2012-10-01 2016-05-11 Univ Pennsylvania COMPOSITIONS AND METHOD FOR TARGETING CURRIC ACIDS FOR THE TREATMENT OF CANCER
NO2760138T3 (cs) 2012-10-01 2018-08-04
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
JP2014105159A (ja) * 2012-11-22 2014-06-09 Nippon Koden Corp ヒト由来上皮細胞接着分子に対するモノクローナル抗体、およびこれを用いた循環腫瘍細胞の検出方法
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US9371366B2 (en) 2012-12-18 2016-06-21 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9574000B2 (en) 2012-12-19 2017-02-21 Medimmune, Llc Anti-human B7-H4 antibodies and their uses
KR20150100715A (ko) 2012-12-21 2015-09-02 앰플리뮨, 인크. 항-h7cr 항체
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
AU2014244333B2 (en) 2013-03-13 2019-02-07 Sanofi-Aventis U.S. Llc Compositions comprising anti-CD38 antibodies and carfilzomib
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2014144763A2 (en) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
EP2970489A2 (en) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
WO2014144960A2 (en) 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Fc variants
EP3216804A3 (en) 2013-03-15 2017-12-20 AbbVie Biotechnology Ltd. Anti-cd25 antibodies and their uses
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
WO2014179601A2 (en) 2013-05-02 2014-11-06 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
CA2914924A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceuticals B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
AU2014342528A1 (en) 2013-10-28 2016-04-28 Dots Technology Corp. Allergen detection
WO2015073575A2 (en) 2013-11-12 2015-05-21 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
WO2015088346A1 (en) 2013-12-13 2015-06-18 Rijksuniversiteit Groningen Antibodies against staphylococcus aureus and uses thereof.
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
SG11201607203XA (en) 2014-03-21 2016-09-29 Regeneron Pharma Non-human animals that make single domain binding proteins
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
WO2015164364A2 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
EP3888690A3 (en) 2014-05-16 2021-10-20 MedImmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
EP3164129A1 (en) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
KR102833621B1 (ko) 2014-07-17 2025-07-14 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
MA39070A1 (fr) 2014-07-31 2017-11-30 Sanofi Sa Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
EP3183002B1 (en) 2014-08-21 2021-03-03 Walter Reed Army Institute of Research Monoclonal antibodies for treatment of microbial infections
CN109147874A (zh) 2014-09-02 2019-01-04 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
WO2016069283A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in cart cells and uses thereof
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
US11471487B2 (en) 2014-10-31 2022-10-18 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding T cells
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
PL3218005T3 (pl) 2014-11-12 2023-05-02 Seagen Inc. Związki oddziałujące z glikanami i sposoby ich zastosowania
CN111620861A (zh) 2014-12-09 2020-09-04 艾伯维公司 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
EP3735990A1 (en) 2014-12-09 2020-11-11 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
HUE052771T2 (hu) 2014-12-11 2021-05-28 Pf Medicament C10orf54 elleni antitestek és alkalmazásuk
EP3233897B1 (en) 2014-12-19 2021-02-17 Universite de Nantes Anti il-34 antibodies
EP3789039A1 (en) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
HK1245134A1 (zh) 2015-01-14 2018-08-24 The Brigham And Women's Hospital, Inc. 用抗lap单克隆抗体治疗癌症
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
WO2016122738A1 (en) 2015-01-31 2016-08-04 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell delivery of therapeutic molecules
JP6970017B2 (ja) 2015-02-09 2021-11-24 メモリアル スローン ケタリング キャンサー センター ヒトａ３３抗原とｄｏｔａ金属複合体に親和性を有する多重特異性抗体及びその使用
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
CN115368460A (zh) 2015-03-17 2022-11-22 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
PL3447075T3 (pl) 2015-05-15 2024-04-29 The General Hospital Corporation Przeciwciała antagonistyczne wobec nadrodziny receptorów czynnika martwicy nowotworów
HRP20201031T1 (hr) 2015-05-29 2020-10-16 Agenus Inc. Anti-ctla-4 protutijela i postupci njihove upotrebe
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
TW201720459A (zh) 2015-11-02 2017-06-16 妮翠斯製藥公司 Ntn1中和劑與抑制後生控制之藥物之組合治療
WO2017076492A1 (en) 2015-11-03 2017-05-11 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
SG11201803213XA (en) 2015-11-12 2018-05-30 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
WO2017091745A1 (en) 2015-11-25 2017-06-01 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
CA3006596A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. Anti-hulrrc15 antibody drug conjugates and methods for their use
JP2019501124A (ja) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
ES2861587T3 (es) 2015-12-31 2021-10-06 Progastrine Et Cancers S A R L Composiciones y métodos para detectar y tratar el cáncer de esófago
CN108700586B (zh) 2015-12-31 2024-08-23 Syncerus有限责任公司 用于评估癌症发生的风险的组合物和方法
PL3397964T3 (pl) 2015-12-31 2022-02-07 Progastrine Et Cancers S.À R.L. Kompozycje i sposoby do wykrywania i leczenia raka jajnika
WO2017114975A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating gastric cancer
ES2843974T3 (es) 2016-03-17 2021-07-21 Tillotts Pharma Ag Anticuerpos anti-TNF alfa y fragmentos funcionales de los mismos
EP3430044A1 (en) 2016-03-17 2019-01-23 Numab Innovation AG Anti-tnf alpha -antibodies and functional fragments thereof
US10787508B2 (en) 2016-03-17 2020-09-29 Numab Innovation Ag Anti-TNFα-antibodies and functional fragments thereof
RS61374B1 (sr) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
BR112018017165A2 (pt) 2016-03-17 2019-01-02 Numab Innovation Ag anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos
KR20180138205A (ko) 2016-03-22 2018-12-28 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
US20190144503A1 (en) 2016-04-27 2019-05-16 Regents Of The University Of Minnesota Methods for the identification of bifunctional compounds
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
US20170348429A1 (en) 2016-05-17 2017-12-07 Abbvie Biotherapeutics Inc. ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
CN109415441B (zh) 2016-05-24 2023-04-07 英斯梅德股份有限公司 抗体及其制备方法
EP3995511A1 (en) 2016-05-27 2022-05-11 AbbVie Biotherapeutics Inc. Anti-cd40 antibodies and their uses
NZ749355A (en) 2016-05-27 2023-04-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
WO2017205745A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
HUE053356T2 (hu) 2016-06-08 2021-06-28 Abbvie Inc B7-H3 elleni antitestek és antitest-hatóanyag konjugátumok
KR20190079713A (ko) 2016-06-13 2019-07-05 아이-맵 항-pd-l1 항체 및 이것의 사용
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
EP3487521A4 (en) 2016-07-21 2020-07-01 Emory University ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
PT3512547T (pt) 2016-09-14 2020-12-11 Abbvie Biotherapeutics Inc Anticorpos anti-pd-1
PE20190633A1 (es) 2016-09-19 2019-04-26 I Mab Anticuerpos anti-gm-csf y usos de los mismos
EP3515950A4 (en) * 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
AU2017330346C1 (en) 2016-09-21 2025-03-06 Nextcure, Inc. Antibodies for Siglec-15 and methods of use thereof
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
TWI843168B (zh) 2016-10-11 2024-05-21 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
MA46779A (fr) 2016-11-02 2019-09-11 Health Research Inc Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20230037664A (ko) 2016-12-07 2023-03-16 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
PE20190921A1 (es) 2016-12-07 2019-06-26 Agenus Inc Anticuerpos y metodos de su utilizacion
HRP20201259T1 (hr) 2016-12-15 2020-11-13 Abbvie Biotherapeutics Inc. Protutijela protiv ox40 i njihova upotreba
KR102679324B1 (ko) 2017-01-05 2024-06-28 네트리 파르마 네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료
TWI771361B (zh) 2017-01-20 2022-07-21 大陸商大有華夏生物醫藥集團有限公司 人程序性死亡受體pd-1的單株抗體及其片段
JP7303750B2 (ja) * 2017-01-24 2023-07-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 癌における非古典的ｈｌａ－ｉおよびネオ抗原を含む複合体を標的とするための方法および組成物
UA126571C2 (uk) 2017-01-24 2022-11-02 Ай-Маб Байофарма Юес Лімітед Антитіло до cd73 та його застосування
EP3574012A1 (en) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
MA47678A (fr) * 2017-03-03 2021-05-26 Treos Bio Ltd Plateforme personnalisée d'identification de peptide immunogène
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
BR112019020414A2 (pt) 2017-03-30 2020-06-09 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
EP3602060B1 (en) 2017-03-30 2022-07-20 Progastrine et Cancers S.à r.l. Compositions and methods for treating lung cancer
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
MA50956A (fr) 2017-04-13 2020-10-14 Agenus Inc Anticorps anti-cd137 et procédés d'utilisation correspondants
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
EP3615052B1 (en) 2017-04-27 2023-01-25 The University of Hong Kong Use of hcn inhibitors for treatment of cancer
CA3062061A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
BR112019023249A8 (pt) 2017-05-05 2021-02-23 Centre For Probe Dev And Commercialization anticorpos monoclonais igf-1r e usos dos mesmos
US11191854B2 (en) 2017-05-05 2021-12-07 Centre For Probe Development And Commercialization Pharmacokinetic enhancements of bifunctional chelates and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
KR20250139417A (ko) 2017-05-31 2025-09-23 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
EP3652210A1 (en) 2017-07-14 2020-05-20 CytomX Therapeutics, Inc. Anti-cd166 antibodies and uses thereof
EP3658178A1 (en) 2017-07-27 2020-06-03 Nomocan Pharmaceuticals LLC Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
US11021540B2 (en) 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
US20190160089A1 (en) 2017-10-31 2019-05-30 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
CA3083345A1 (en) 2017-11-27 2019-05-31 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
EP3720879B1 (en) 2017-12-05 2022-05-11 Progastrine et Cancers S.à r.l. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
JP2021508443A (ja) 2017-12-15 2021-03-11 アレタ・バイオセラピューティクス・インコーポレイテッドＡｌｅｔａ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Ｃｄ１９変異体
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
US12180285B2 (en) 2018-02-01 2024-12-31 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
US20200400675A1 (en) 2018-02-27 2020-12-24 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
AU2019234468A1 (en) 2018-03-12 2020-10-01 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
CA3092387A1 (en) 2018-04-02 2019-10-10 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US11970532B2 (en) 2018-05-10 2024-04-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
CN110540588B (zh) * 2018-05-28 2022-08-23 香港中文大学 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
EA202190092A1 (ru) 2018-06-21 2021-05-18 Юманити Терапьютикс, Инк. Композиции и способы лечения и профилактики неврологических расстройств
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
WO2020015722A1 (en) 2018-07-19 2020-01-23 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-1 antibodies, dosages and uses thereof
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
KR20210070300A (ko) 2018-10-03 2021-06-14 스태튼 바이오테크놀로지 비.브이. 사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
WO2020086328A1 (en) 2018-10-25 2020-04-30 The Medical College Of Wisconsin, Inc. Targeting clptm1l for treatment and prevention of cancer
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
KR20210068591A (ko) 2018-10-31 2021-06-09 주식회사 인투셀 융합된 헤테로시클릭 벤조디아제핀 유도체 및 그의 용도
BR112021010799A2 (pt) 2018-12-03 2021-08-24 Fusion Pharmaceuticals Inc. Terapia combinada com radioimunoconjugados e inibidor do ponto de verificação
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
US12422441B2 (en) 2018-12-07 2025-09-23 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
AU2019427766A1 (en) 2019-01-30 2021-09-16 Nomocan Pharmaceuticals Llc Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
WO2020168555A1 (zh) 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3抗原结合片段及其应用
JP7668534B2 (ja) 2019-02-26 2025-04-25 インスピアーナ， インコーポレイテッド 高親和性抗ｍｅｒｔｋ抗体およびその使用
AU2020241428A1 (en) 2019-03-15 2021-08-12 Cartesian Therapeutics, Inc. Anti-BCMA chimeric antigen receptors
CN120944827A (zh) 2019-03-27 2025-11-14 宾夕法尼亚大学董事会 Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
CA3151110A1 (en) 2019-08-16 2021-02-25 Children's Hospital Medical Center Methods of treating a subject with a cdc42-specific inhibitor
CA3152027A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
JP7628111B2 (ja) 2019-09-03 2025-02-07 バイオ － テラ ソリューションズ、リミテッド 抗ｔｉｇｉｔ免疫阻害剤及び応用
JP2022549504A (ja) 2019-09-26 2022-11-25 エスティーキューブ アンド カンパニー グリコシル化ｃｔｌａ－４に対して特異的な抗体およびその使用方法
CN114829404B (zh) 2019-10-09 2025-09-09 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
JP2023500530A (ja) 2019-11-04 2023-01-06 コード バイオセラピューティクス インコーポレイテッド 脳特異的血管新生抑制因子１（ｂａｉ１）抗体及びその使用
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
JP2023516080A (ja) 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
JP2023517889A (ja) 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
US20240228592A1 (en) 2020-03-31 2024-07-11 Bio-Thera Solutions, Ltd. Antibody and fusion protein for treating coronaviruses and use thereof
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
IL297538A (en) 2020-04-24 2022-12-01 Millennium Pharm Inc Anti-cd19 antibodies and uses thereof
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
EP4194468A4 (en) 2020-08-07 2025-07-16 Bio Thera Solutions Ltd ANTI PD-L1 ANTIBODY AND ITS USE
WO2022056490A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Chimeric antigen receptors for treatment of cancer
CN114437227A (zh) 2020-11-06 2022-05-06 百奥泰生物制药股份有限公司 双特异抗体及其应用
EP4253415A4 (en) 2020-11-12 2024-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
WO2022116952A1 (zh) * 2020-12-01 2022-06-09 苏州克睿基因生物科技有限公司 靶向cd70的抗原结合蛋白及其应用
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
US20250326855A1 (en) 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CN114230656B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与食道癌驱动基因突变相关的抗原肽组合及其应用
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4320149A1 (en) 2021-04-09 2024-02-14 Takeda Pharmaceutical Company Limited Antibodies targeting complement factor d and uses therof
US20230111279A1 (en) 2021-04-26 2023-04-13 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
MX2023011712A (es) 2021-04-26 2023-10-12 Millennium Pharm Inc Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
WO2022235628A1 (en) 2021-05-04 2022-11-10 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Antibodies against interleukin 9 and methods of using them
US20240352481A1 (en) 2021-07-29 2024-10-24 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
WO2023023491A1 (en) 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
AU2022328625A1 (en) 2021-08-17 2024-03-21 Eli Lilly And Company Bispecific anti-flt3/cd3 antibodies and methods of use
US12467921B2 (en) 2021-08-31 2025-11-11 Versitech Limited Antibodies and assays for detection of Burkholderia mallei
US20250136701A1 (en) 2021-09-03 2025-05-01 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (ja) 2021-09-03 2024-09-26 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｌａｍｐ１抗体およびその使用
EP4410839A4 (en) 2021-09-30 2025-10-08 Bio Thera Solutions Ltd ANTI-B7-H3 ANTIBODY AND ITS USE
CA3235627A1 (en) 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
EP4466291A4 (en) 2022-01-28 2025-07-16 Georgiamune Inc ANTIBODIES DIRECTED AGAINST PROGRAMMED CELL DEATH PROTEIN 1, PD-1 AGONISTS
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
KR20230144960A (ko) 2022-04-07 2023-10-17 트윈피그바이오랩(주) 신규 펩타이드 기반 면역항암제
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024012539A1 (zh) 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体及其应用
CN119546339A (zh) 2022-07-15 2025-02-28 丹尼斯科美国公司 用于产生单克隆抗体的方法
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024133858A1 (en) 2022-12-22 2024-06-27 Julius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
AU2024207469A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
TW202448960A (zh) 2023-02-07 2024-12-16 美商Ｇｏ治療公司 包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
WO2024180085A1 (en) 2023-02-27 2024-09-06 Netris Pharma Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains
EP4431526A1 (en) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof
KR20250160358A (ko) 2023-03-16 2025-11-12 인매진 피티이. 엘티디. Ilt7-표적화 항체 및 그의 용도
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025049272A1 (en) 2023-08-25 2025-03-06 The Broad Institute, Inc. Card9 variant polypeptide and antibodies directed thereto
TW202515903A (zh) 2023-10-12 2025-04-16 瑞士商百濟神州瑞士有限責任公司 手術前後基於抗ｐｄ－１之治療
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025235420A1 (en) 2024-05-06 2025-11-13 Generate Biomedicines, Inc. Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
WO2025235419A1 (en) 2024-05-06 2025-11-13 Generate Biomedicines, Inc. Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
SE9102074D0 (sv) * 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) * 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU6113396A (en) * 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens

Also Published As

Publication number Publication date
CZ294425B6 (cs) 2005-01-12
NO994983L (no) 1999-12-07
HUP0100794A1 (hu) 2001-06-28
SI0970126T1 (en) 2001-08-31
JP3876002B2 (ja) 2007-01-31
EP0970126A2 (en) 2000-01-12
PT970126E (pt) 2001-10-30
DK0970126T3 (da) 2001-08-13
IL132062A (en) 2007-02-11
TR199902553T2 (xx) 2000-03-21
HU221818B1 (hu) 2003-01-28
EP0970126B1 (en) 2001-04-18
US7227002B1 (en) 2007-06-05
JP2001519824A (ja) 2001-10-23
DE69800716T2 (de) 2001-09-20
AU742045B2 (en) 2001-12-13
KR100663319B1 (ko) 2007-01-02
BRPI9809391B8 (pt) 2021-05-25
IL132062A0 (en) 2001-03-19
KR20050052549A (ko) 2005-06-02
WO1998046645A2 (en) 1998-10-22
BR9809391A (pt) 2000-06-13
AU7643198A (en) 1998-11-11
KR20010006340A (ko) 2001-01-26
CA2286879A1 (en) 1998-10-22
GR3036229T3 (en) 2001-10-31
CN100387621C (zh) 2008-05-14
PL193780B1 (pl) 2007-03-30
CA2286879C (en) 2003-12-16
ES2172149T3 (es) 2002-09-16
HK1026911A1 (en) 2000-12-29
DE69800716D1 (de) 2001-05-23
PL344190A1 (en) 2001-10-08
CZ361499A3 (cs) 2000-04-12
BRPI9809391B1 (pt) 2016-03-15
CU23268A3 (es) 2008-03-14
KR100516133B1 (ko) 2005-09-21
ATE200679T1 (de) 2001-05-15
RU2224766C2 (ru) 2004-02-27
NO994983D0 (no) 1999-10-13
CN1252076A (zh) 2000-05-03
WO1998046645A3 (en) 1999-04-15
HUP0100794A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
NO315904B1 (no) Fremgangsmåte for fremstilling av anti-human antigenreseptor, humant antistoff, samt av farmasöytisk preparat
US7632925B2 (en) Antibodies that bind human 17-A1/EpCAM tumor antigen
US7435549B1 (en) Method of identifying binding site domains that retain the capacity of binding to an epitope
Huston et al. Engineered antibodies take center stage
US20100240100A1 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
CN116322755A (zh) 一种结合cd70的抗体、嵌合抗原受体（car）及其应用
JP7627258B2 (ja) 抗ｂｃｍａ抗体、その抗原結合断片、及びそれらの医療用途
KR102290335B1 (ko) Cd30을 표적으로 하는 키메라 항원 수용체 및 이의 용도
JP2025528835A (ja) Ｍｓｌｎに対する抗体及びその使用方法
WO2025214438A1 (zh) 结合cd19和/或cd22的抗原结合分子及其用途
CN119751675A (zh) 靶向baff-r的全人源抗体及其car-t治疗的应用
HK1026911B (en) Novel method for the production of antihuman antigen receptors and uses thereof
AU2002349969A1 (en) Human antibodies that have MN binding and cell adhesion-neutralizing activity
HK1031740B (en) Method of identifying binding site domains that retain the capacity of binding to an epitop

Legal Events

Date Code Title Description
MK1K Patent expired